Topical Absorbable Hemostats Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update

Pages: 170 Published: June 24, 2022 Report Code: GDME1390EPD

Topical absorbable hemostats are agents used to promote and accelerate hemostasis to control bleeding in cases where application of pressure, ligature and other conventional methods is ineffective. They are inserted to remove excess blood, thereby preventing further bleeding and clearing up the operating site for the surgeon.

The topical absorbable hemostats market research report reviews details of major pipeline products which includes, product description, licensing and collaboration details, and other developmental activities. The report also reviews the major players involved in the development of topical absorbable hemostats and lists all their pipeline projects.

Which are the key territories in the topical absorbable hemostats pipeline market?

The key territories in the topical absorbable hemostats pipeline market are the United States, Europe, India, South Korea, China, Japan, Canada, Russia, Singapore, Taiwan, the United Kingdom, Vietnam, Australia, and Philippines. The United States has the highest number of pipeline products.

Topical absorbable hemostats pipeline market, by territories

Topical absorbable hemostats pipeline market, by territories

For more territory insights, download a free report sample

Which are the key categories in the topical absorbable hemostats pipeline market?

The key categories in the topical absorbable hemostats pipeline market are Collagen Based Hemostats, Oxidized Regenerated Cellulose Based Hemostats, Thrombin Based Hemostats, Polysaccharide Based Hemostats, Combination Hemostats – Pads, and Gelatin Based Hemostats. Collagen Based Hemostats has the highest number of pipeline products.

Topical absorbable hemostats pipeline market, by categories

Topical absorbable hemostats pipeline market, by categories

For more category insights, download a free report sample

Which are the key regulatory paths in the topical absorbable hemostats pipeline market?

The key regulatory paths in the topical absorbable hemostats pipeline market are 510(k), CE, PMA, ICAC, NMPA, MDITAC, MDL, NIFDS, Ninsho, HSA, BOPA, Shonin, TGA, and UKCA. 510(k) has the highest number of pipeline products.

Topical absorbable hemostats pipeline market, by companies

Topical absorbable hemostats pipeline market, by companies

For more regulatory path insights, download a free report sample

Which are the key companies in the topical absorbable hemostats pipeline market?

The key companies in the topical absorbable hemostats pipeline market are 3-D Matrix Ltd, Acro Biomedical Co Ltd, Advanced Biotech Products Pvt Ltd, Angiotech Pharmaceuticals Inc, Anika Therapeutics Inc, APRUS Bio-Medical Innovations Pvt Ltd, Arch Therapeutics Inc, Baxter Healthcare Corp, Beth Israel Deaconess Medical Center, Biomedica Management Corp, Biom’Up SAS, and Cellphire Inc.

Market report overview

Key territories The United States, Europe, India, South Korea, China, Japan, Canada, Russia, Singapore, Taiwan, the United Kingdom, Vietnam, Australia, and Philippines
Key categories Collagen Based Hemostats, Oxidized Regenerated Cellulose Based Hemostats, Thrombin Based Hemostats, Polysaccharide Based Hemostats, Combination Hemostats – Pads, and Gelatin Based Hemostats
Key regulatory paths 510(k), CE, PMA, ICAC, NMPA, MDITAC, MDL, NIFDS, Ninsho, HSA, BOPA, Shonin, TGA, and UKCA
Key companies 3-D Matrix Ltd, Acro Biomedical Co Ltd, Advanced Biotech Products Pvt Ltd, Angiotech Pharmaceuticals Inc, Anika Therapeutics Inc, APRUS Bio-Medical Innovations Pvt Ltd, Arch Therapeutics Inc, Baxter Healthcare Corp, Beth Israel Deaconess Medical Center, Biomedica Management Corp, Biom’Up SAS, and Cellphire Inc

Scope

  • Extensive coverage of the Topical Absorbable Hemostats under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Topical Absorbable Hemostats and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy

The report enables you to:

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Topical Absorbable Hemostats under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Key Players

3-D Matrix Ltd

Advamedica Inc

Angiotech Pharmaceuticals Inc

Anika Therapeutics Inc

APRUS Bio-Medical Innovations Pvt Ltd

Arch Therapeutics Inc

Baxter Healthcare Corp

Beth Israel Deaconess Medical Center

Biomedica Management Corp

Biom’Up SAS

Cellphire Inc

Ceramicos Para Aplicacoes Medicas SA

Columbia University

Covalent Medical, Inc. (Inactive)

Covalon Technologies Ltd

CR Bard Inc

Cresilon Inc

Endomedix Incorporated

Entegrion Inc

Ethicon US LLC

ETX Pharma Inc

Gamma Therapeutics Inc

GATT Technologies BV

Haemostatix Ltd

Hemostasis LLC

HLL Lifecare Ltd

Ichor Sciences LLC

Keratin Biosciences Inc

Leader Biomedical Europe BV

Medcura Inc

Protege Biomedical LLC

Resorba GmbH

Rice University

Sanofi Biosurgery Inc

Sea Run Holdings Inc

St Teresa Medical Inc

STB Lifesaving Technologies

Tectum

The Medicines Co

Therus Corporation

Thrombotargets Corp

United Health Products, Inc.

University of Grenoble Alpes

Virginia Commonwealth University

Xcede Technologies Inc

Z-Medica LLC

Table of Contents

1 Table of Contents 3

|1.1 List of Tables 7

|1.2 List of Figures 12

2 Introduction 13

2.1 Topical Absorbable Hemostats Overview 13

3 Products under Development 14

3.1 Topical Absorbable Hemostats – Pipeline Products by Stage of Development 14

3.2 Topical Absorbable Hemostats – Pipeline Products by Segment 15

3.3 Topical Absorbable Hemostats – Pipeline Products by Territory 16

3.4 Topical Absorbable Hemostats – Pipeline Products by Regulatory Path 17

3.5 Topical Absorbable Hemostats – Pipeline Products by Estimated Approval Date 18

3.6 Topical Absorbable Hemostats – Ongoing Clinical Trials 19

4 Topical Absorbable Hemostats – Pipeline Products under Development by Companies 20

4.1 Topical Absorbable Hemostats Companies – Pipeline Products by Stage of Development 20

4.2 Topical Absorbable Hemostats – Pipeline Products by Stage of Development 22

5 Topical Absorbable Hemostats Companies and Product Overview 24

5.1 3-D Matrix Ltd Company Overview 24

5.1.1 3-D Matrix Ltd Pipeline Products & Ongoing Clinical Trials Overview 24

5.2 Acro Biomedical Co Ltd Company Overview 30

5.2.1 Acro Biomedical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 30

5.3 Advanced Biotech Products Pvt Ltd Company Overview 31

5.3.1 Advanced Biotech Products Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 31

5.4 Angiotech Pharmaceuticals Inc Company Overview 32

5.4.1 Angiotech Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 32

5.5 Anika Therapeutics Inc Company Overview 33

5.5.1 Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 33

5.6 APRUS Bio-Medical Innovations Pvt Ltd Company Overview 34

5.6.1 APRUS Bio-Medical Innovations Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 34

5.7 Arch Therapeutics Inc Company Overview 35

5.7.1 Arch Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 35

5.8 Baxter Healthcare Corp Company Overview 39

5.8.1 Baxter Healthcare Corp Pipeline Products & Ongoing Clinical Trials Overview 39

5.9 Beth Israel Deaconess Medical Center Company Overview 41

5.9.1 Beth Israel Deaconess Medical Center Pipeline Products & Ongoing Clinical Trials Overview 41

5.10 Biomedica Management Corp Company Overview 42

5.10.1 Biomedica Management Corp Pipeline Products & Ongoing Clinical Trials Overview 42

5.11 Biom’Up SAS Company Overview 45

5.11.1 Biom’Up SAS Pipeline Products & Ongoing Clinical Trials Overview 45

5.12 Cellphire Inc Company Overview 47

5.12.1 Cellphire Inc Pipeline Products & Ongoing Clinical Trials Overview 47

5.13 Ceramicos Para Aplicacoes Medicas SA Company Overview 51

5.13.1 Ceramicos Para Aplicacoes Medicas SA Pipeline Products & Ongoing Clinical Trials Overview 51

5.14 Columbia University Company Overview 52

5.14.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview 52

5.15 Covalent Medical, Inc. (Inactive) Company Overview 53

5.15.1 Covalent Medical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 53

5.16 Covalon Technologies Ltd Company Overview 54

5.16.1 Covalon Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 54

5.17 CR Bard Inc Company Overview 56

5.17.1 CR Bard Inc Pipeline Products & Ongoing Clinical Trials Overview 56

5.18 Cresilon Inc Company Overview 58

5.18.1 Cresilon Inc Pipeline Products & Ongoing Clinical Trials Overview 58

5.19 Endomedix Incorporated Company Overview 60

5.19.1 Endomedix Incorporated Pipeline Products & Ongoing Clinical Trials Overview 60

5.20 Entegrion Inc Company Overview 62

5.20.1 Entegrion Inc Pipeline Products & Ongoing Clinical Trials Overview 62

5.21 Ethicon US LLC Company Overview 63

5.21.1 Ethicon US LLC Pipeline Products & Ongoing Clinical Trials Overview 63

5.22 ETX Pharma Inc Company Overview 65

5.22.1 ETX Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview 65

5.23 Gamma Diagnostics Inc Company Overview 66

5.23.1 Gamma Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 66

5.24 GATT Technologies BV Company Overview 67

5.24.1 GATT Technologies BV Pipeline Products & Ongoing Clinical Trials Overview 67

5.25 Haemostatix Ltd Company Overview 69

5.25.1 Haemostatix Ltd Pipeline Products & Ongoing Clinical Trials Overview 69

5.26 Hemostasis LLC Company Overview 71

5.26.1 Hemostasis LLC Pipeline Products & Ongoing Clinical Trials Overview 71

5.27 HLL Lifecare Ltd Company Overview 75

5.27.1 HLL Lifecare Ltd Pipeline Products & Ongoing Clinical Trials Overview 75

5.28 Ichor Sciences LLC Company Overview 76

5.28.1 Ichor Sciences LLC Pipeline Products & Ongoing Clinical Trials Overview 76

5.29 Keratin Biosciences Inc Company Overview 77

5.29.1 Keratin Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 77

5.30 Leader Biomedical Europe BV Company Overview 78

5.30.1 Leader Biomedical Europe BV Pipeline Products & Ongoing Clinical Trials Overview 78

5.31 Medcura Inc Company Overview 79

5.31.1 Medcura Inc Pipeline Products & Ongoing Clinical Trials Overview 79

5.32 Protege Biomedical LLC Company Overview 82

5.32.1 Protege Biomedical LLC Pipeline Products & Ongoing Clinical Trials Overview 82

5.33 Resorba GmbH Company Overview 83

5.33.1 Resorba GmbH Pipeline Products & Ongoing Clinical Trials Overview 83

5.34 Rice University Company Overview 85

5.34.1 Rice University Pipeline Products & Ongoing Clinical Trials Overview 85

5.35 Sanofi Biosurgery Inc Company Overview 86

5.35.1 Sanofi Biosurgery Inc Pipeline Products & Ongoing Clinical Trials Overview 86

5.36 Sea Run Holdings Inc Company Overview 88

5.36.1 Sea Run Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 88

5.37 St Teresa Medical Inc Company Overview 89

5.37.1 St Teresa Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 89

5.38 STB Lifesaving Technologies Company Overview 91

5.38.1 STB Lifesaving Technologies Pipeline Products & Ongoing Clinical Trials Overview 91

5.39 Tectum Company Overview 92

5.39.1 Tectum Pipeline Products & Ongoing Clinical Trials Overview 92

5.40 The Medicines Co Company Overview 94

5.40.1 The Medicines Co Pipeline Products & Ongoing Clinical Trials Overview 94

5.41 Therus Corporation Company Overview 95

5.41.1 Therus Corporation Pipeline Products & Ongoing Clinical Trials Overview 95

5.42 Thrombotargets Corp Company Overview 96

5.42.1 Thrombotargets Corp Pipeline Products & Ongoing Clinical Trials Overview 96

5.43 United Health Products, Inc. Company Overview 100

5.43.1 United Health Products, Inc. Pipeline Products & Ongoing Clinical Trials Overview 100

5.44 University of Grenoble Alpes Company Overview 105

5.44.1 University of Grenoble Alpes Pipeline Products & Ongoing Clinical Trials Overview 105

5.45 Virginia Commonwealth University Company Overview 106

5.45.1 Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview 106

5.46 Xcede Technologies Inc Company Overview 107

5.46.1 Xcede Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 107

5.47 Z-Medica LLC Company Overview 111

5.47.1 Z-Medica LLC Pipeline Products & Ongoing Clinical Trials Overview 111

6 Topical Absorbable Hemostats- Recent Developments 114

6.1 Jun 10, 2022: Anika to Participate in the Sidoti Small Cap Virtual Investor Conference 114

6.2 Jun 08, 2022: Baxter to Host Second-Quarter 2022 Financial Results Conference Call for Investors 114

6.3 May 27, 2022: Medtronic reports full year and fourth quarter fiscal year 2022 financial results 114

6.4 May 26, 2022: Medtronic reports full year and fourth quarter fiscal year 2022 financial results announces 8% dividend increase 114

6.5 May 25, 2022: Baxter Highlights Business Strategies and Innovation at 2022 Investor Conference 114

6.6 May 16, 2022: Analysts Anticipate Artivion to Announce $0.09 Earnings Per Share 115

6.7 May 13, 2022: Cadila Pharma appoints Jawed Zia as CEO 115

6.8 May 12, 2022: Johnson & Johnson to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference 115

6.9 May 11, 2022: Johnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Health Company 115

6.10 May 10, 2022: Johnson & Johnson MedTech Adds New CFO to the Mix 116

6.11 May 10, 2022: Baxter to Host 2022 Investor Conference 116

6.12 May 09, 2022: Anika to Participate in the UBS Global Healthcare Conference 2022 116

6.13 May 05, 2022: Anika Reports First Quarter Fiscal 2022 Financial Results 116

6.14 May 03, 2022: Sanofi: Annual General Meeting of May 3, 2022 120

6.15 May 02, 2022: Johnson & Johnson to Participate in the Bernstein 38th Annual Strategic Decisions Conference 120

6.16 Apr 27, 2022: Merit Medical Reports Results for Quarter Ended March 31, 2022 120

6.17 Apr 21, 2022: Artivion Announces Release Date and Teleconference Call Details for First Quarter 2022 Financial Results 122

6.18 Apr 21, 2022: Merit Medical Announces Chief Operating Officer Transition 122

6.19 Apr 20, 2022: Johnson & Johnson to Participate in the UBS Global Healthcare Conference 122

6.20 Apr 19, 2022: Johnson & Johnson Reports Q1 2022 Results 122

6.21 Apr 07, 2022: Anika to Issue First Quarter 2022 Financial Results on Thursday, May 5, 2022 124

6.22 Apr 07, 2022: Johnson & Johnson to Participate in the BofA Securities 2022 Healthcare Conference 124

6.23 Apr 04, 2022: Anika to Participate in the 21st Annual Needham Virtual Healthcare Conference 124

6.24 Mar 15, 2022: Johnson & Johnson to Host Investor Conference Call on First-Quarter Results 124

6.25 Mar 10, 2022: Anika to Participate in the Canaccord Genuity Musculoskeletal Conference 125

6.26 Mar 09, 2022: Artivion to Host Investor & Analyst Day on March 23, 2022 125

6.27 Mar 08, 2022: Anika Reports Fourth Quarter and Year-End 2021 Financial Results 125

6.28 Feb 22, 2022: Sanara MedTech Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2021 127

6.29 Feb 15, 2022: Johnson & Johnson Names Darius Adamczyk, Chairman and Chief Executive Officer of Honeywell, to its Board of Directors 127

6.30 Feb 10, 2022: Baxter to Present at Citi’s 2022 Virtual Healthcare Conference 128

6.31 Feb 09, 2022: Johnson & Johnson to Participate in the Raymond James 43rd Annual Institutional Investors Conference 128

6.32 Feb 08, 2022: Anika to Issue Fourth Quarter and Year-End 2021 Financial Results on Tuesday, March 8, 2022 128

6.33 Feb 07, 2022: Johnson & Johnson to Participate in the Cowen 42nd Annual Health Care Virtual Conference 128

6.34 Jan 27, 2022: Johnson & Johnson to Participate in Citi’s 2022 Virtual Healthcare Conference 129

6.35 Jan 25, 2022: Johnson & Johnson Reports Q4 and Full-Year 2021 Results 129

6.36 Jan 06, 2022: Baxter to Host Fourth-Quarter 2021 Financial Results Conference Call for Investors 130

6.37 Jan 04, 2022: Medtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference 130

6.38 Jan 04, 2022: Arch Therapeutics Announces Appointment of Guy Fish to the Board 130

6.39 Dec 22, 2021: Sanara MedTech Announces the Retirement of J. Michael Carmena and Appointment of Eric Tanzberger to its Board of Directors 131

6.40 Dec 22, 2021: United Health Products provides regulatory status update 131

6.41 Dec 15, 2021: Sanara MedTech Announces the Appointment of Roszell Mack III to its Board of Directors 131

6.42 Dec 13, 2021: Covalon Announces Strong Year End and Fourth Quarter Results for Fiscal 2021 132

6.43 Dec 10, 2021: Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results 133

6.44 Dec 08, 2021: Johnson & Johnson to Participate in the 40th Annual J.P. Morgan Healthcare Conference 134

6.45 Dec 08, 2021: Dr Jens von Lackum appointed to the Management Board of B. Braun SE 134

6.46 Nov 18, 2021: Anika to Participate in Upcoming Investor Conferences 134

6.47 Nov 08, 2021: IntelliCentrics and EUCARE Announce Strategic Partnership Supporting Delivery of Taiwan’s High-Quality, Integrated Medical Services to the World 135

6.48 Nov 04, 2021: Anika Reports Third Quarter 2021 Financial Results 135

6.49 Nov 02, 2021: Baxter to Present at Evercore ISI 4th Annual HealthCONx Conference 138

6.50 Nov 01, 2021: Anika Appoints Sheryl Conley to Board of Directors 138

6.51 Oct 28, 2021: Sanofi announces strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER 139

6.52 Oct 28, 2021: Merit Medical Reports Results For Quarter Ended September 30, 2021 149

6.53 Oct 18, 2021: Anika to Issue Third Quarter 2021 Financial Results on Thursday, November 4, 2021 150

6.54 Oct 13, 2021: Baxter to Present at Credit Suisse 30th Annual Virtual Healthcare Conference 150

6.55 Oct 12, 2021: Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson To Retire, Effective December 31, 2021 150

6.56 Oct 12, 2021: Johnson & Johnson Announces Jessica Moore as Vice President of Investor Relations 152

6.57 Oct 11, 2021: Johnson & Johnson to Participate in the Credit Suisse 30th Annual Healthcare Conference 152

6.58 Oct 05, 2021: Merit Medical Systems to Announce Third Quarter Results on October 28, 2021 152

6.59 Sep 27, 2021: Baxter to Host Third-Quarter 2021 Financial Results Conference Call for Investors 153

6.60 Sep 22, 2021: Anthony Semedo Joins CryoLife Board of Directors 153

6.61 Sep 16, 2021: Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results 153

6.62 Sep 09, 2021: Merit Medical Systems to Announce First Quarter Results on April 29, 2021 154

6.63 Sep 07, 2021: Anika to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference 154

6.64 Aug 30, 2021: Covalon Announces Fiscal 2021 Q3 Results 154

6.65 Aug 19, 2021: Alex Gorsky to Serve as Executive Chairman and Transition Role of Chief Executive Officer of Johnson & Johnson to Joaquin Duato, Effective January 3, 2022 155

6.66 Aug 12, 2021: Johnson & Johnson to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference 158

6.67 Aug 09, 2021: Johnson & Johnson to Participate in Barclays Global Consumer Staples Virtual Conference 158

6.68 Jul 29, 2021: Baxter Reports Second-Quarter 2021 Results 158

6.69 Jul 29, 2021: Sanofi announces half-year financial report for period ending June 30, 2021 160

6.70 Jul 29, 2021: Baxter to Present at UBS Genomics

2.0 and MedTech Innovations Summit 161

6.71 Jul 29, 2021: CryoLife Reports Second Quarter 2021 Financial Results 161

6.72 Jul 27, 2021: Johnson & Johnson to Participate in the Virtual Wells Fargo Healthcare Conference 162

6.73 Jul 27, 2021: Stryker reports second quarter 2021 operating results 162

6.74 Jul 21, 2021: Johnson & Johnson Reports 2021 Second-Quarter Results 163

6.75 Jul 19, 2021: Anika to Issue Second Quarter 2021 Financial Results on Thursday, August 5, 2021 164

6.76 Jul 15, 2021: CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2021 Financial Results 164

6.77 Jul 09, 2021: Merit Medical Systems to Announce Second Quarter Results on July 29, 2021 165

6.78 Jul 07, 2021: Advanced Medical Solutions Group: Half year trading update 165

6.79 Jun 30, 2021: B. Braun Announces Jennifer Prioleau as New Chief Legal Officer and Chief Compliance Officer 166

7 Appendix 167

7.1 Methodology 167

7.2 About GlobalData 169

7.3 Contact Us 170

7.4 Disclaimer 170

List of Tables

Topical Absorbable Hemostats – Pipeline Products by Stage of Development 14

Topical Absorbable Hemostats – Pipeline Products by Segment 15

Topical Absorbable Hemostats – Pipeline Products by Territory 16

Topical Absorbable Hemostats – Pipeline Products by Regulatory Path 17

Topical Absorbable Hemostats – Pipeline Products by Estimated Approval Date 18

Topical Absorbable Hemostats – Ongoing Clinical Trials 19

Topical Absorbable Hemostats Companies – Pipeline Products by Stage of Development 20

Topical Absorbable Hemostats – Pipeline Products by Stage of Development 22

3-D Matrix Ltd Pipeline Products & Ongoing Clinical Trials Overview 24

PuraStat – Product Status 24

PuraStat – Product Description 25

TDM-623 – Product Status 25

TDM-623 – Product Description 25

3-D Matrix Ltd – Ongoing Clinical Trials Overview 26

PuraStat – A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of Purastat Absorbable Haemostatic Material for the Management of Bleeding after Open Liver Resection 27

PuraStat – A Multicenter Prospective Observational Study to Evaluate the Utilization, Effectiveness and Safety of Purastat in the Management of Gastrointestinal Bleeding 27

PuraStat – A Study to Evaluate the Effectiveness of Purastat in the Prevention of Delayed Bleeding after EMR of Non-ampullary Duodenal Lesions 28

PuraStat – Efficacy of PuraStat for the Prevention of Delayed Bleeding after Endoscopic Resection of Colorectal Lesions 28

PuraStat – Endoscopically-delivered Purastat for the Treatment of Haemorrhagic Radiation Proctopathy: A Randomised Feasibility Study 28

PuraStat – The Hemostatic Potential of TDM-621 on Ascending Aortic Surgery 29

Acro Biomedical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 30

ACROHCM – Product Status 30

ACROHCM – Product Description 30

Advanced Biotech Products Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 31

Hemocoll – Product Status 31

Hemocoll – Product Description 31

Angiotech Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 32

Hemaseel Thrombin Haemostatic Agent – Product Status 32

Hemaseel Thrombin Haemostatic Agent – Product Description 32

Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 33

Hemostatic Patch – Product Status 33

Hemostatic Patch – Product Description 33

APRUS Bio-Medical Innovations Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 34

Deep Wound Hemostat – Product Status 34

Deep Wound Hemostat – Product Description 34

Arch Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 35

AC5 – Burns – Product Status 35

AC5 – Burns – Product Description 36

AC5 – Diabetic Ulcers – Product Status 36

AC5 – Diabetic Ulcers – Product Description 36

AC5 – Pressure Ulcers – Product Status 37

AC5 – Pressure Ulcers – Product Description 37

AC5 – V – Product Status 37

AC5 – V – Product Description 38

AC5 Surgical Hemostatic Device – Product Status 38

AC5 Surgical Hemostatic Device – Product Description 38

Baxter Healthcare Corp Pipeline Products & Ongoing Clinical Trials Overview 39

Celstat Topical Hemostatic Dressing – Product Status 39

Celstat Topical Hemostatic Dressing – Product Description 39

PerClot – Product Status 40

PerClot – Product Description 40

Beth Israel Deaconess Medical Center Pipeline Products & Ongoing Clinical Trials Overview 41

Portable Wound Hemostasis System – Product Status 41

Portable Wound Hemostasis System – Product Description 41

Biomedica Management Corp Pipeline Products & Ongoing Clinical Trials Overview 42

ClotFoam – Product Status 42

ClotFoam – Product Description 42

ClotGel – Product Status 43

ClotGel – Product Description 43

ClotSpray – Product Status 43

ClotSpray – Product Description 44

Biom’Up SAS Pipeline Products & Ongoing Clinical Trials Overview 45

HEMOSNOW – Product Status 45

HEMOSNOW – Product Description 46

Cellphire Inc Pipeline Products & Ongoing Clinical Trials Overview 47

Thromboderm – Product Status 47

Thromboderm – Product Description 47

Thrombosomes – Product Status 48

Thrombosomes – Product Description 48

Cellphire Inc – Ongoing Clinical Trials Overview 49

Thrombosomes – A Phase I, Multi-center, Open-label, Dose Escalation Study of Thrombosomes in Bleeding Thrombocytopenic Patients in Three Cohorts 50

Ceramicos Para Aplicacoes Medicas SA Pipeline Products & Ongoing Clinical Trials Overview 51

HemoKi – Product Status 51

HemoKi – Product Description 51

Columbia University Pipeline Products & Ongoing Clinical Trials Overview 52

Hemostatic Wound Dressing – Product Status 52

Hemostatic Wound Dressing – Product Description 52

Covalent Medical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 53

CovaSTAT – Product Status 53

CovaSTAT – Product Description 53

Covalon Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 54

ColActive THP – Product Status 54

ColActive THP – Product Description 54

CovaStat BioActive Absorbable Hemostatic Sponge – Product Status 55

CovaStat BioActive Absorbable Hemostatic Sponge – Product Description 55

CR Bard Inc Pipeline Products & Ongoing Clinical Trials Overview 56

Absorbable Hemostat – Product Status 56

Absorbable Hemostat – Product Description 56

New Hemostat 1 – Product Status 57

New Hemostat 1 – Product Description 57

New Hemostat 2 – Product Status 57

New Hemostat 2 – Product Description 57

Cresilon Inc Pipeline Products & Ongoing Clinical Trials Overview 58

Hemostatic Gel – Product Status 58

Hemostatic Gel – Product Description 58

TRAUMAGEL – Product Status 59

TRAUMAGEL – Product Description 59

Endomedix Incorporated Pipeline Products & Ongoing Clinical Trials Overview 60

Surgical Hemostat – Intracranial Surgery – Product Status 60

Surgical Hemostat – Intracranial Surgery – Product Description 60

Topical Hemostat – Product Status 61

Topical Hemostat – Product Description 61

Entegrion Inc Pipeline Products & Ongoing Clinical Trials Overview 62

Stasix – Product Status 62

Stasix – Product Description 62

Ethicon US LLC Pipeline Products & Ongoing Clinical Trials Overview 63

Next Gen Hemostat Kit – Product Status 63

Next Gen Hemostat Kit – Product Description 63

SURGIFLO – Sterile Field Preparation – Product Status 64

SURGIFLO – Sterile Field Preparation – Product Description 64

ETX Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview 65

ETX-302 – Product Status 65

ETX-302 – Product Description 65

Gamma Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 66

GammaTF – Product Status 66

GammaTF – Product Description 66

GATT Technologies BV Pipeline Products & Ongoing Clinical Trials Overview 67

GATT-Patch – Product Status 67

GATT-Patch – Product Description 67

GATT-Powder – Product Status 68

GATT-Powder – Product Description 68

Haemostatix Ltd Pipeline Products & Ongoing Clinical Trials Overview 69

Haemoplax – Product Status 69

Haemoplax – Product Description 69

PeproStat – Product Status 70

PeproStat – Product Description 70

Hemostasis LLC Pipeline Products & Ongoing Clinical Trials Overview 71

ACCEL Absorbable Hemostat – Product Status 71

ACCEL Absorbable Hemostat – Product Description 71

ENT Hemostat – Product Status 72

ENT Hemostat – Product Description 72

Hemostatic Gel – Product Status 72

Hemostatic Gel – Product Description 72

Hemostasis LLC – Ongoing Clinical Trials Overview 73

ACCEL Absorbable Hemostat – ACCEL Absorbable Hemostat Powder Clinical Trial 74

HLL Lifecare Ltd Pipeline Products & Ongoing Clinical Trials Overview 75

Hinstat Ext – Product Status 75

Hinstat Ext – Product Description 75

Ichor Sciences LLC Pipeline Products & Ongoing Clinical Trials Overview 76

Statbond ENT – Product Status 76

Statbond ENT – Product Description 76

Keratin Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 77

Keratin-Based Hemostat – Product Status 77

Keratin-Based Hemostat – Product Description 77

Leader Biomedical Europe BV Pipeline Products & Ongoing Clinical Trials Overview 78

Collagen-Based Haemostatic Device – Product Status 78

Collagen-Based Haemostatic Device – Product Description 78

Medcura Inc Pipeline Products & Ongoing Clinical Trials Overview 79

Hemogrip Foam – Product Status 79

Hemogrip Foam – Product Description 79

LifeFoam – Product Status 80

LifeFoam – Product Description 80

LifeGel – Product Status 80

LifeGel – Product Description 81

Protege Biomedical LLC Pipeline Products & Ongoing Clinical Trials Overview 82

Ionic Hemostatic Mineral Bandage – Emergency Trauma – Product Status 82

Ionic Hemostatic Mineral Bandage – Emergency Trauma – Product Description 82

Resorba GmbH Pipeline Products & Ongoing Clinical Trials Overview 83

Antibiotic Hemostat – Product Status 83

Antibiotic Hemostat – Product Description 83

RESORBA – Cardiac Surgery – Product Status 84

RESORBA – Cardiac Surgery – Product Description 84

Rice University Pipeline Products & Ongoing Clinical Trials Overview 85

KOD Hydrogel Hemostat – Product Status 85

KOD Hydrogel Hemostat – Product Description 85

Sanofi Biosurgery Inc Pipeline Products & Ongoing Clinical Trials Overview 86

LeSeal – Product Status 86

LeSeal – Product Description 86

Lumagel – Product Status 87

Lumagel – Product Description 87

Sea Run Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 88

SEA-STAT – Product Status 88

SEA-STAT – Product Description 88

St Teresa Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 89

Surgiclot – Product Status 89

Surgiclot – Product Description 89

WRAPCLOT – Product Status 90

WRAPCLOT – Product Description 90

STB Lifesaving Technologies Pipeline Products & Ongoing Clinical Trials Overview 91

FAST Dressing – Product Status 91

FAST Dressing – Product Description 91

Tectum Pipeline Products & Ongoing Clinical Trials Overview 92

Hemostatic Gel – Product Status 92

Hemostatic Gel – Product Description 92

Wound Dressing With Hemostat – Product Status 92

Wound Dressing With Hemostat – Product Description 93

The Medicines Co Pipeline Products & Ongoing Clinical Trials Overview 94

Fibropad Patch – Product Status 94

Fibropad Patch – Product Description 94

Therus Corporation Pipeline Products & Ongoing Clinical Trials Overview 95

Therus Acoustic Hemostasis System – Product Status 95

Therus Acoustic Hemostasis System – Product Description 95

Thrombotargets Corp Pipeline Products & Ongoing Clinical Trials Overview 96

Next Generation TT-173 – Product Status 96

Next Generation TT-173 – Product Description 96

TT-173 – Product Status 97

TT-173 – Product Description 97

Thrombotargets Corp – Ongoing Clinical Trials Overview 98

TT-173 – A Phase II/III, Randomized, Controlled, Single Blind Study to Evaluate the Haemostatic Efficacy and Safety of Topically Applied TT-173 in Patients Undergoing Knee Arthroplasty 99

United Health Products, Inc. Pipeline Products & Ongoing Clinical Trials Overview 100

HemoStyp – Surgical Wounds – Product Status 100

HemoStyp – Surgical Wounds – Product Description 100

HemoStyp – Trauma – Product Status 101

HemoStyp – Trauma – Product Description 101

HemoStyp External Procedure Gauze – Product Status 101

HemoStyp External Procedure Gauze – Product Description 102

HemoStyp hydrocolloid – Product Status 102

HemoStyp hydrocolloid – Product Description 102

HemoStyp Internal Procedure Gauze – Product Status 103

HemoStyp Internal Procedure Gauze – Product Description 103

Hemostyp Internal Procedure Gauze – Orthopedic – Product Status 103

Hemostyp Internal Procedure Gauze – Orthopedic – Product Description 104

HemoStyp Trauma Gauze – Product Status 104

HemoStyp Trauma Gauze – Product Description 104

University of Grenoble Alpes Pipeline Products & Ongoing Clinical Trials Overview 105

Bleeding Controlling Device – Product Status 105

Bleeding Controlling Device – Product Description 105

Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview 106

BioHemostat – Product Status 106

BioHemostat – Product Description 106

Xcede Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 107

Xcede – Femoral Artery – Product Status 107

Xcede – Femoral Artery – Product Description 107

Xcede – Laparoscopic Surgery – Product Status 108

Xcede – Laparoscopic Surgery – Product Description 108

Xcede – Lung Sealing – Product Status 108

Xcede – Lung Sealing – Product Description 108

Xcede – Vascular Surgery – Product Status 109

Xcede – Vascular Surgery – Product Description 109

Xcede Patch – Liver Resection – Product Status 109

Xcede Patch – Liver Resection – Product Description 110

Z-Medica LLC Pipeline Products & Ongoing Clinical Trials Overview 111

QuikClot Control+ – Class I and Class II Bleeding – Product Status 111

QuikClot Control+ – Class I and Class II Bleeding – Product Description 111

Z-Medica LLC – Ongoing Clinical Trials Overview 112

QuikClot Control+ – Class I and Class II Bleeding – A Cardiac Investigational Device Exemption Study to Evaluate the Efficacy of QuikClot Control+ for Class I and II Bleeding in Patients Undergoing Cardiac Surgery 113

Glossary 169

List of Figures

Topical Absorbable Hemostats – Pipeline Products by Stage of Development 14

Topical Absorbable Hemostats – Pipeline Products by Segment 15

Topical Absorbable Hemostats – Pipeline Products by Territory 16

Topical Absorbable Hemostats – Pipeline Products by Regulatory Path 17

Topical Absorbable Hemostats – Pipeline Products by Estimated Approval Date 18

Topical Absorbable Hemostats – Ongoing Clinical Trials 19

Frequently Asked Questions

Request a Free Sample
$4000

Can be used by individual purchaser only

$12000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.